Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 27;3(8):2398-2415.
doi: 10.3390/ph3082398.

Combinations of drugs in the Treatment of Obesity

Bruno Halpern  1 , Eduardo S L Oliveira  2 , André M Faria  3 , Alfredo Halpern  4 , Maria Edna de Melo  5 , Cintia Cercato  6 , Marcio C Mancini  7
Affiliations
Review

Combinations of drugs in the Treatment of Obesity

Bruno Halpern et al. Pharmaceuticals (Basel). .

Abstract

Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.

Keywords: 5-hydroxytryptophan; antidepressants; bupropion; caffeine; carbidopa; drug combination; ephedrine; fenfluramine; glucagon-like peptide-1; leptin; metformin; metreleptin; naltrexone; noradrenergic drugs; orlistat; peptide YY; phentermine; pramlintide; sibutramine; topiramate; zonisamide.

PubMed Disclaimer

References

    1. Global Strategy on Diet, Physical Activity and Health. World Health Organization; Geneva, Switzerland: 2010. [(accessed on 12 June 2010)]. Available online: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/pr...
    1. Flegal K.M., Graubard B.I., Williamson D.F., Gail M.H. Cause specific excess deaths associated with underweight, overweight and obesity. J. Am. Med. Assoc. 2007;298:2028–2037. - PubMed
    1. Douketis J.D., Macie C., Thabane L., Williamson D.F. Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice. Int. J. Obes. (Lond.) 2005;29:1153–1167. - PubMed
    1. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C.W. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. Br. Med. J. 2007;335:1194–1199. - PMC - PubMed
    1. Bray G.A. Lifestyle and pharmacological approaches to weight loss: Efficacy and safety. J. Clin. Endocrinol. Metab. 2008;93:S81–S88. - PMC - PubMed

LinkOut - more resources